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Objective: Patients with positivity for the human immunodeﬁciency virus (HIVþ) present low
concentrations of antioxidant nutrients, including total glutathione (GSH) and its precursors. We
investigated the responses of the sulfur-containing amino acid pathway to cysteine and glutamine
(Gln) dietary supplements in patients with HIVþ compared with healthy controls.
Methods: Twelve treated patients (six men and six women, 22–45 y old) and 20 healthy controls
(10 men and 10 women, 20–59 y old) were randomly assigned to 7-d dietary supplements con-
taining N-acetylcysteine (NAC; 1 g/d) or Gln (20 g/d), with a 7-d washout period ingesting their
usual diet. Blood samples were drawn after an overnight fast. High-performance liquid chro-
matographic plasma analysis of sulfur-containing amino acids (methionine, homocysteine,
cysteine, and taurine), GSH, oxidized GSH, and serine, glycine, glutamic acid, and Gln was carried
out moments before and after 7-d supplementations. Statistical comparisons were undertaken
between groups and between dietary supplements (P < 0.05).
Results: Patients with HIVþ showed higher oxidized GSH and lower concentrations of GSH and all
amino acids except homocysteine. The HIVþ group responded to the NAC by increased levels of
sulfur-containing amino acids and GSH and equalized taurine and GSH levels in the control group.
The Gln supplements also equalized the levels of GSH, Gln, and glycine in the control group.
Conclusion: An increase in GSH may be attained by NAC or Gln supplementation, with NAC acting
by increasing cysteine levels and Gln likely acting by replenishing the glycine pool (trial registered
at http://www.clinicaltrials.gov, identiﬁer NCT00910442).
 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Several studies have shown that patients infected with the
human immunodeﬁciency virus (HIVþ) present a deﬁciency of
antioxidant nutrients, including total glutathione (GSH) and its
precursors [1–4], thus contributing to disease progression.
The virus and lymphocytes use hydrogen peroxide (H2O2) to
signal their survival and function. H2O2 is generated near the cello Paulo State Foundation)
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Research Council).
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).
sevier OA license.membrane, where lymphocytes establish contact with mitogens,
viruses, and other activation agents [5]. The generated H2O2 is
rapidly inactivated by local peroxidases, mostly by GSH peroxi-
dase, resulting in oxidized GSH (GSSG), which is converted back
to reduced GSH by the enzyme GSH reductase to maintain the
reduced intracellular status [6].
Glutathione (L-g-glutamyl-L-cysteinyl-glycine) is the major
intracellular hydrosoluble antioxidant agent responsible for
important functions in biochemical processes and cell control,
especially antioxidant defenses and immune responses. This
agent is necessary for lymphocyte proliferation, antibody-
dependent and cell-mediated cytotoxicity, and the protection
of lymphocytes against superoxides produced to destroy
invading pathogens [5]. The content of GSH in mammalian cells
Table 1
Subjects’ demographic, anthropometric, and biochemical data at baseline
Variables Controls Patients with HIVþ P
Age (y) 24 (23–28) 27 (25–36) 0.070
BMI (kg/m2) 25 (3.1) 25 (3.0) 0.960
g-GT (IU/L) 24.9 (14.7) 52.7 (21.7) <0.001
Urea (mg/dL) 29.0 (7.4) 34.1 (6.4) 0.061
Creatinine (mg/dL) 0.9 (0.83–1.1) 0.9 (0.8–1.05) 0.726
Albumin (g/dL) 4.1 (0.3) 3.9 (0.4) 0.112
Folate (ng/mL) 7.5 (6.3–9.0) 1.9 (1.4–6.6) 0.017
Vitamin B12 (pg/mL) 288 (130) 367 (139) 0.115
Calcium (mg/dL) 9.2 (9.0–9.4) 8.7 (7.8–9.6) 0.425
Glucose (mg/dL) 87 (83.5–91) 103 (93.5–117) 0.001
TG (mg/dL) 88 (66.5–117) 191 (111–247) 0.002
TC (mg/dL) 165.6 (26.7) 222 (45.6) <0.001
HDL-C (mg/dL) 52.5 (19.9) 38.3 (17.9) 0.052
LDL-C (mg/dL) 90.6 (32.9) 146.7 (31.6) <0.001
BMI, body mass index; g-GT, g-glutamyl transpeptidase; HDL-C, high-density
lipoprotein cholesterol; HIVþ, positive for the human immunodeﬁciency virus;
LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, tri-
acylglycerols
Data are presented as median (25th–75th percentiles) or mean (SD).
M. D. Borges-Santos et al. / Nutrition 28 (2012) 753–756754is dynamically maintained by the g-glutamyl cycle, which
provides a substrate for transpeptidases located on their external
membranes. Tissues that present low transpeptidase activity
(the liver, pancreas, and muscle) export GSH, which is carried by
the blood to cells that have high transpeptidase activity, such as
kidney cells [5,7]. Plasma GSH arises largely from the liver. It can
also be used as a mechanism for cysteine storage and transport,
with consequences for the regulation of signal transduction
pathways and gene transcription [8]. Conversely, cysteine is
known to be the rate-limiting substrate for GSH resynthesis [9,
10]. Cysteine is also the main source of taurine, a protective
antioxidant that enables the antigen-presenting cells to promote
the proliferation of T lymphocytes [11].
Improving cysteine availability for the biosynthesis of GSH is
the most extensively studied approach for increasing the cell
GSH pool. Among the agents tested are N-acetyl-L-cysteine
(NAC), lipoic acid, cysteamine, and 2-oxothiazolidine
4-carboxylate. Other reducing agents, such as dithiocarbamate,
b-mercaptoethanol, and dithiothreitol, can also improve GSH
synthesis through the extracellular reduction of cystine to
cysteine. NAC and a-lipoic acid have generated the most interest
because of their proved clinical safety features and efﬁcacy
in vivo.
N-acetyl-L-cysteine is a well-characterized antioxidant that
counteracts the effects of reactive oxygen intermediates in living
cells, thus preventing the activation of nuclear factor-kB by H2O2
[12]. Oral NAC has been found to increase GSH in the plasma,
muscle, and bronchoalveolar lavage ﬂuid [13–15]. Oral L-gluta-
mine (Gln) increases Gln levels in the plasma of healthy subjects
[16] and has been shown to improve plasma GSH levels and
signiﬁcantly increase lean body mass in HIV infection [2]. The
two precursors inﬂuence GSH biosynthesis through different
pathways and provoke isolated and synergistic effects on
patients’ immunology and clinical improvements. Therefore, we
investigated not only the status of GSH and its precursor in
patients with HIVþ supplemented with NAC or Gln and but also
possible approaches for augmenting their GSH content.
Materials and methods
Subjects
The HIVþ group was composed of 12 patients (6 men and 6 women, 22–45 y
old) who had been diagnosed clinically and in the laboratory by viral load
(enzyme-linked immunosorbent assay and western blotting detection methods)
and CD4þ and CD8þ lymphocyte counts (ﬂow cytometry). All patients had been
under highly active antiretroviral treatment for at least 1 y, receiving one HIV
protease inhibitor (indinavir 800 mg twice daily, n ¼ 10; or ritonavir 600 mg
twice daily, n ¼ 2) in combination with two nucleoside analogs (zidovudine 250
mg plus lamivudine 150 mg twice daily, n ¼ 11; or lamivudine 150 mg plus
stavudine 40 mg twice daily, n ¼ 1). The exclusion criteria were the presence of
any renal or liver failure and the ingestion of GSH precursors or any form of
vitamin B. The healthy control group consisted of 20 adults (10 men and 10
women, 20–59 y old) who were negative for HIV and clinically healthy. Written
informed consent was obtained from all subjects, and the study was approved by
the ethics committee of the Botucatu Medical School.
Design
At baseline, all selected subjects underwent an anthropometric assessment
for body mass index (kilograms per meter squared) calculation and had fasting
blood drawn (12 mL) to analyze markers for glomerular ﬁltration (creatinine
and urea) and hepatocyte injury marker (g-glutamyl transpeptidase), nutri-
tional variables (albumin, calcium, folate, and vitamin B12), glucose, lipids
(triacylglycerols and cholesterol fractions), and uric acid. Folate and vitamin B12
were assayed by chemiluminescence (Immulite System, Siemens Healthcare
Diagnostics, Marburg, Germany), and the others by a dry chemistry method
(Vitros System, Ortho Clinical Diagnostics, Johnson & Johnson Company,
Raritan, NJ, USA).The two groups were randomly assigned to different dietary supplements
(NAC 1 g/d or Gln 20 g/d) with their usual diet as the baseline and washout in
a crossover design. All dietary supplements were administered throughout the
consecutive 7-d period preceded and followed by fasting blood sampling. The
high-performance liquid chromatographic (LC10AD System, Shimadzu, Kyoto,
Japan) analysis included plasma free amino acids (methionine, serine, taurine,
glycine, andGln), glutamic acid quantiﬁed by themethod of Halawa et al. [17], and
plasmahomocysteine and cysteines quantiﬁed according to themethodof Ubbink
et al. [18]. For total GSH, aliquots of plasma were incubated with dithiothreitol,
deproteinized by perchloric acid, and derivatized with o-phthalaldehyde. For
GSSG, the blood, having been previously blocked by n-ethylmaleimide, was then
processed for total GSH [19].
Statistical analysis
All statistical analyses were performed using SAS 8.01 (SAS Institute, Cary,
NC, USA). Parametric and non-parametric variables were expressed, respectively,
as mean (standard deviation) and median (interquartile range, 25th–75th
percentiles). A general linear model procedure for repeated measures using type
III sums of squares statistics was used to test the interaction between groups
(HIVþ and control groups) and/or dietary supplements (NAC, washout, and Gln).
An adjusted g-regression model was used for the non-parametric variables. The
groups and/or dietary supplements with minimal signiﬁcant differences were
compared based on generalized estimating equations. A 5% signiﬁcance level
was set.
Results
Characteristics of the subjects before the dietary supple-
mentation are presented in Table 1. Thirty-two subjects
completed the intervention program.
Compared with the usual diet, the NAC and Gln supplements
increased GSH, taurine, methionine, and Gln and decreased
serine in patients with HIVþ (P < 0.05). In addition, NAC
supplementation led to signiﬁcant increases in cysteine and
homocysteine, whereas Gln supplementation increased glycine
concentrations (Table 2).
Among the three GSH precursors, plasma glutamic acid and
glycine concentrations increased signiﬁcantly after Gln supple-
mentation, whereas cysteine was augmented by NAC; however,
only glycine reached the control values, whereas glutamic acid
and cysteine remained decreased (Table 2).
The NAC and Gln supplements showed similar effects on
plasma levels of methionine, taurine, glutamic acid, and Gln
(Table 2). Nevertheless, NAC supplementation produced stronger
effects than Gln by increasing GSH, cysteine, and homocysteine
levels, whereas Gln produced a speciﬁc effect on glycine
(Table 2).
Table 2
Plasma amino acid and glutathione concentrations in different dietary
conditions*
Amino acid
and group
Usual
diet
N-acetylcysteine Glutamine Washout
Methionine
(mmol/L)
Control 30.8  8.8 30.3  9.6 30.3  9.6 31.9  8.6
HIVþ 20  6.6z 24.7  7.4y 25.5  11 24.3  7.7y,z
Homocysteine
(mmol/L)
Control 13.9  5.5 13.7  2.5 11.3  2.7y 13.8  5.3
HIVþ 9.8  1.6z 12.4  3y 10.2  1.3 9.8  1.5z
Serine
(mmol/L)
Control 108  7.8 110  12 112  14 113  11y
HIVþ 86.9  20z 61  17.2y,z 60.6  17y,z 63.8  19.3y,z
Cysteine
(mmol/L)
Control 413  175 534  54y 420  177 409  180
HIVþ 158  10z 251  32y,z 175  26y,z 169  13y,z
Taurine
(mmol/L)
Control 63.2  3.9 68.8  9.6y 63.2  3.9 65.4  10.5
HIVþ 48.1  3.7z 57.2  4.9y,z 57.2  5.6y,z 66.4  10.4y,z
Glutamate
(mmol/L)
Control 94  18.5 133  27y 144  29y 113  23y
HIVþ 56.4  11.3z 63.9  14y,z 64.1  14y,z 63.6  14.7y,z
Glycine
(mmol/L)
Control 485  68.5 481  76 480  76 483  73
HIVþ 371  20.2z 347  63z 472  60y 329  75y,z
Glutamine
(mmol/L)
Control 476  84 565  85.3 565  85.4 477  100
HIVþ 285  59z 341  56.9z 341  57z 287  64z
GSH (mmol/L)
Control 9.2  2.1 8.5  0.9 8.3  0.8y 8.7  1.4
HIVþ 4.9  0.7y,z 9.2  0.9y,z 8.4  0.4y,z 5.8  0.7y,z
GSSG (mmol/L)
Control 0.77  0.86 0.58  0.31 0.48  0.23 0.44  0.26
HIVþ 1.44  0.4z 1.76  0.5z 1.81  0.17z 1.64  0.14z
GSSG/GSH
(mmol/L)
Control 0.08  0.07 0.07  0.04 0.06  0.03 0.05  0.04
HIVþ 0.29  0.06z 0.19  0.04y,z 0.2  0.02y,z 0.28  0.02z
GSH, reduced glutathione; GSSG, oxidized glutathione; HIVþ, positive for human
immunodeﬁciency virus
* All values are presented as mean  SD. Data were analyzed using repeated-
measures analysis of variance. A signiﬁcant group-by-treatment interaction was
observed for all amino acids except glutamine and GSSG (P < 0.05).
y Signiﬁcantly different from the habitual diet (baseline; P < 0.05).
z Signiﬁcantly different from control at the same time point (P < 0.05).
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Although highly active antiretroviral treatment has been
demonstrated to increase antioxidant defenses [20], the data
from the present work showed that the antioxidant deﬁcit per-
sisted as indicated by the higher levels of oxidative stress
markers, such as GSSG.
Therefore, patients with HIVþ have coexisting infection,
oxidative stress, and antiretroviral therapy. In this sense, it is
necessary to determine the emergent role of micronutrients,
particularly those with antioxidant actions (e.g., selenium and
zinc) and immune function to minimize the effects of such
metabolic disorders as lipodystrophy, insulin resistance, and
dyslipidemia, which contribute to the morbidities of this coin-
fection [21,22].
The decreased GSH concentrations observed in this study
have been found previously in patients with HIVþ [20–23]. GSHdecreases in response to low-protein ingestion or speciﬁc deﬁcits
of its component amino acids [24]. In the present work, the two
groups had their usual diet as the baseline and washout, in
addition to similarly presenting with overweight and normal
albuminemia, thus excluding a low-protein intake situation.
Lower plasma GSH in the HIVþ group followed the lack of its
components, cysteine, glutamic acid, and glycine, which in turn
paralleled the lower levels of their precursors methionine and
serine (for cysteine) and Gln (for glutamic acid). Therefore, the
lower GSH concentration could be due to an increased usage
associated with low synthesis secondary to the decrease in the
availability of substrates [21,22]. It is known that, in pathologic
conditions, the three amino acid precursors of GSH synthesis
(Gln, glycine, and cysteine) become essential [25].
Decreases in cysteine and sulfate levels are provoked by liver
GSH synthesis and muscle cysteine catabolism, respectively.
Moreover, the consistently increased proﬁle of cytokines (espe-
cially interleukin-1, interleukin-6, and tumor necrosis factor-a)
can aggravate muscle catabolism in these patients, increase the
demand for amino acids, and compromise the adaptive response
in HIV infection [20,26].
One of the proposed mechanisms for this massive loss is the
controlled protein catabolism that excretes cysteine to spare
protein nitrogen and restrain the catabolism [27]. Cysteine
catabolism produces sulfate and protons, thus favoring Gln
synthesis and preserving nitrogen from the amino acid pool in
the form of Gln. However, in patients with HIVþ, the adaptive
response is not achieved, and they lose thiol homeostasis [26].
The present data showed that the NAC and Gln supplements
increased GSH availability. In a study carried out by Jahoor et al.
[21], only an increase of the cysteine supply modiﬁed the GSH
synthesis in individuals with HIVþ, because the levels of the
other two constituent amino acids (glutamic acid and glycine)
were normal [21]. In the present study, all three amino acid
levels were lower than those of controls at baseline and below
the reference values for the healthy population [17]. These
results agree with ﬁndings in prior studies showing deﬁciencies
of cysteine and Gln in patients with HIVþ [26,28].
The NAC supplementation almost doubled the level of GSH,
signiﬁcantly surpassing the control group. Although cysteine and
taurine levels increased, the resulting values were still below
those of controls. NAC supplementation has been reported to
increase plasma and muscular GSH and cysteine levels in a dose-
dependent response [10]. The present use of 1.0 g/d did not result
in cysteine normalization in the plasma. This was shown by an
increase of the cysteine concentration, although it did not reach
the level in healthy subjects. In the fasting state, cysteine is
maintained mostly by the GSH turnover [4], whereas after
methionine loading, most cysteine might originate from the
transsulfuration pathway [29].
Available estimates have suggested that the endogenous
formation of glycine is 5- to 10-fold higher than the dietary
intake [30]. Most of the glycine pool arises from glutamic acid
metabolism, but glycine and serine are readily interchangeable
by the enzymatic step catalyzed by serine hydroxyl methyl
transferase. Choline, by dimethylglycine, also contributes to
glycine for GSH synthesis in humans [31]. Total glycine ﬂow is
determined mainly by the direct conversion to serine synthesis
by serine hydroxyl methyl transferase (41%) and glycine decar-
boxylation for the generation of 1-carbon units and CO2
production (39%) [32].
Serine decreased signiﬁcantly with NAC and Gln supple-
mentations. Serine is consumed by the direct formation of
glycine (through the serine hydroxyl methyl transferase
M. D. Borges-Santos et al. / Nutrition 28 (2012) 753–756756pathway) or by cysteine formation through the transsulfuration
pathway from homocysteine to cystathionine. Only glycine
reached the control levels and that occurred with glutamic acid
supplementation.
In the case of cysteine concentrations, it appears that NAC
supplementation led to some plasma increase of cysteine, which
slowed the transsulfuration pathway, sparing homocysteine
(which increased signiﬁcantly) and serine. The existing serine
was then diverted from the cysteine to the glycine pathway,
which was consumed with the spared cysteine (from NAC) to
normalize GSH levels.
The increase of plasma homocysteine concentrations (>10
mmol/L) with NAC may be due to the decreased consumption of
homocysteine by remethylation tomethionine (reduced folate in
this case) or, more likely, by transsulfuration to cysteine (spared
by NAC).
The Gln-induced GSH increase and normalization were prob-
ably achieved by generating glycine (from glutamic acid) and
sparing serine to formcysteine (fromhomocysteine), andall three
(glutamic acid, glycine, and cysteine) together generated GSH.
The NAC and Gln, through different mechanisms, were able to
supply substrates to increase GSH levels. Normalized GSH was
unable to restore cysteine or glutamic acid concentrations to the
normal control level, and neither of the two supplements had
signiﬁcant effects on the GSSG/GSH ratio, indicating a need for an
additional supplement (perhaps riboﬂavin).
Thus, a GSH increase can be achieved by NAC or Gln supple-
mentation, with the former acting by sparing cysteine and the
latter increasing GSH possibly by replenishing the glycine pool.
Only glycine reached control values; therefore, the rate-limiting
step for GSH synthesis may be not completely dependent on
cysteine availability and vice versa.
Conclusion
Acting through replenishment of GSH and by improving
cysteine and taurine, each dietary supplement, NAC and Gln, was
effective, but it would be even better to test the ability of their
combination to strengthen the antioxidative immune compe-
tence of patients with HIVþ.
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